Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; none of the 58 sources its claims cite is checked for support yet.
Abstract
BACKGROUND: The declining efficacy and widespread resistance to antimalarial drugs (AMD) pose significant challenges to global malaria control and elimination efforts. To enhance treatment efficacy, the World Health Organization (WHO) recommends the use of combination therapies. This study aimed to evaluate the therapeutic efficacy of chloroquine with primaquine (CQ-PQ) for the treatment of uncomplicated Plasmodium vivax malaria in the study area. METHODS: The study utilized a single-arm, 42-day follow-up design to assess the therapeutic efficacy and safety of a treatment regimen in Northwest Ethiopia. Participants, all diagnosed with uncomplicated vivax malaria, received a 3-day course of chloroquine (CQ) at 25 mg/kg, followed by a 14-day course of primaquine (PQ) at 0.25 mg/kg. Participants were monitored with follow-up visits on days 1, 2, 3, 7, 14, 21, 28, 35, and 42. Data were double-entered into a standard Excel sheet by the WHO and analysed using SPSS v.26. Statistical analyses included Kaplan-Meier survival analysis, t-tests, and ANOVA, with statistical significance set at p < 0.05. RESULTS: Of the 100 participants enrolled, 92% completed the study. The cumulative treatment success rate for CQ-PQ was 93.7% (95% CI 0.86-0.97) on day 42, with a 6.3% (95% CI 0.03-0.14) treatment failure rate. Asexual parasite clearance was rapid, with 97% achieving clearance by day 2 and full clearance by day 3 in all but one participant. Haemoglobin levels increased significantly from 12.3 g/dL at baseline to 13.5 g/dL by day 42, with 84.2% of mild anaemic patients and 85.7% of moderate anaemic patients showing recovery. Common adverse events included abdominal pain (8%) and diarrhea (5%), all of which resolved by day 7. CONCLUSION: CQ-PQ therapy demonstrated high efficacy in clearing parasitaemia and improving haemoglobin levels in patients with vivax malaria. These results highlight the potential of CQ-PQ as an effective treatment option, with a favourable safety profile. Further studies are needed to explore long-term outcomes and the impact of this treatment on malaria control in different settings.
Overview
CoChat Summary
TL;DR
In a single-arm, 42-day in vivo study in Northwest Ethiopia, chloroquine plus primaquine without G6PD testing achieved a day-42 PCR-uncorrected treatment success rate of 93.7% among 100 enrolled patients with uncomplicated *Plasmodium vivax* malaria. Parasite and fever clearance were rapid, haemoglobin improved, and no severe adverse events or dark urine were reported.
Key findings
- The cumulative CQ–PQ treatment success rate was 93.7% (95% CI 86.4–97.1) on day 42 and 94.7% (95% CI 87.8–97.8) on day 28; treatment failure was 6.3% (95% CI 2.9–13.6) on day 42.
- Asexual parasite clearance was rapid: 47% cleared by day 1, 97% by day 2, and all but one participant by day 3; gametocyte clearance was 73.8% by day 1 and 100% by day 3, with no gametocyte recurrence.
- Mean haemoglobin increased from 12.3 ± 1.11 g/dL at baseline to 13.5 ± 1.126 g/dL by day 42 (p < 0.0001); 84.2% (16/19) of mild anaemic and 85.7% (6/7) of moderate anaemic patients improved, and anaemic patients decreased from 26 to 4.
- No severe adverse events occurred; abdominal pain (8%) and diarrhoea (5%) were most common and resolved by day 7. No dark-coloured urine (Hillmen urine colour chart ≥ 5) was reported.
Methods
- Single-arm, 42-day follow-up in vivo therapeutic efficacy and safety study at Andasa Health Center, Northwest Ethiopia, from November 2022 to March 2023.
- Participants had uncomplicated *P. vivax* mono-infection, asexual parasitaemia ≥ 250/μL, age > 6 months, and lived within 10 km; 2,915 suspected malaria patients were screened, 271 had *P. vivax*, and 100 were enrolled, with 92% completing follow-up.
- Treatment was CQ 25 mg/kg over 3 days plus PQ 0.25 mg/kg daily for 14 days, with follow-up on days 1, 2, 3, 7, 14, 21, 28, 35, and 42; outcomes were classified per WHO as ACPR, ETF, LCF, or LPF, and analysed with Kaplan–Meier survival analysis, t-tests, and ANOVA in SPSS v.26 (p < 0.05).
Limitations
- The paper states there was no PCR genotyping to differentiate relapses from new infections, so results are PCR uncorrected, and no data on CQ drug concentrations were collected to distinguish true resistance from insufficient drug levels.
- The text makes evident that the study was single-arm with no direct CQ monotherapy comparison arm, and it used a convenient sampling technique.
- The study was conducted without G6PD testing; the authors note this was under close Hillmen urine monitoring and in a setting with low reported Ethiopian G6PD deficiency prevalence, but this remains a limitation for interpreting primaquine safety.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
0 Valid · 2 Not valid · 40 Not checked · 80 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“About half of the participants (47%) achieved asexual parasite clearance by day 1 following the first dose of CQ–PQ, increasing to 97% by day 2, and complete clearance in all but one participant by day 3 (Fig. 4); the exception was a 10-year-old child who experienced ETF with a parasitaemia of 3879/μL.”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On day 28 the cumulative success rate and failure rate of CQ–PQ treatment were 94.7% (95% CI 87.8–97.8) and 5.3% (95% CI 2.2–12.2), respectively (Fig. 3, Table 2).”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“About half of the participants (47%) achieved asexual parasite clearance by day 1 following the first dose of CQ–PQ, increasing to 97% by day 2, and complete clearance in all but one participant by day 3 (Fig. 4); the exception was a 10-year-old child who experienced ETF with a parasitaemia of 3879/μL.”
- Also stated in: § Results · plain
“Asexual parasite clearance was rapid, with 97% achieving clearance by day 2 and full clearance by day 3 in all but one participant.”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“About half of the participants (47%) achieved asexual parasite clearance by day 1 following the first dose of CQ–PQ, increasing to 97% by day 2, and complete clearance in all but one participant by day 3 (Fig. 4); the exception was a 10-year-old child who experienced ETF with a parasitaemia of 3879/μL.”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier survival analysis, the cumulative treatment success rate and cumulative treatment failure rate of CQ–PQ treatment on day 42 were 93.7% (95% CI 86.4–97.1) and 6.3% (95% CI 2.9–13.6), respectively.”
- Also stated in: § Results · plain
“The cumulative treatment success rate for CQ–PQ was 93.7% (95% CI 0.86–0.97) on day 42”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
plainstates a causen = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Results · plain
64 more claims
Create a free account to see all 122 claims and to verify the 58 references still open.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 34
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| LPF | F | 14 | Day 28 | 8840 | 1720 | 5.0 |”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
Reported 5 · recomputed 5.139535
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
“LPF was identified in three participants on day 28 (parasitaemia: 1720/μL, 320/μL, and 210/μL)”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Primary outcomes
“| LPF | M | 25 | Day 28 | 1201 | 2120 | 0.6 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Adverse events following CQ–PQ treatment
“After day 3 most of the clinical symptoms and adverse events were improved and all subsided by day 7 (Table 4).”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Adverse events following CQ–PQ treatment
“| Abdominal pain, n (%) | 5 (5%) | 8 (8%) | 6 (6%) | 3 (3%) | 1 (1%) | – |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Baseline socio-demographic characteristics of study participants
“All study participants (n = 100) were urban residents (Table 1).”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Methods > Study setting and design
“The study was carried out in the Bahir Dar Zuria district, which has a total population of 220,581 inhabitants, of whom 112,378 are male and 108,203 are female, with 100% of the population residing in rural areas [18].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Diarrhea, n (%) | 2 (2%) | 5 (4%) | 2 (2%) | 1 (1%) | – | – |”
§ Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study > Results > Adverse events following CQ–PQ treatment
Reported 4 · recomputed 5
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
District Laboratory Practice in Tropical Countries
Cheesbrough, M. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581304 · Cited by 2,651
Cowman, A. F., Healer, J., Marapana, D., & Marsh, K. (2016) · Cell · doi:10.1016/j.cell.2016.07.055 · Cited by 890
White, N. J. (2018) · Malaria Journal · doi:10.1186/s12936-018-2509-9 · Cited by 563
PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?
Rieckmann, K. H., Davis, D. R., & Hutton, D. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91792-3 · Cited by 501
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price, R. N., von Seidlein, L., Valecha, N., Nosten, F., Baird, J. K., & White, N. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70855-2 · Cited by 388
Chloroquine Resistance in Plasmodium vivax
Baird, J. K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4075-4083.2004 · Cited by 335
Tuteja, R. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05997.x · Cited by 302
The anaemia of Plasmodium vivax malaria
Douglas, N. M., Anstey, N. M., Buffet, P. A., Poespoprodjo, J. R., Yeo, T. W., White, N. J., & Price, R. N. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-135 · Cited by 249
White, N. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-1731-1 · Cited by 230
Guidelines for Malaria Vector Control
Choi, L., Pryce, J., Richardson, M., Lutje, V., Walshe, D., & Garner, P. (2019) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 150
Research works printed but not linked: 2
- WHO. World malaria report 2024. Geneva: World Health Organization; 2024.
- WHO. Malaria eradication: benefits, future scenarios and feasibility. A report of the strategic advisory group on malaria eradication. Geneva: World Health Organization; 2020.
Cited by
From Conventional to Nano‐Enabled Combination Therapies to Address Therapeutic Challenges of Malaria
Eissa, M. M., & Fadel, E. (2026) · Drug Development Research · doi:10.1002/ddr.70395
Wijayanti, D., & Hartayu, T. S. (2025) · Community Medicine and Education Journal · doi:10.37275/cmej.v6i2.803
Debash, H., Tilahun, M., Desale, S., Getnet, E., & Mohammed, A. E. (2026) · Scientific Reports · doi:10.1038/s41598-026-58540-9
Dugassa, D., Gamachu, B., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., Kassa, M., & Brhane, B. G. (2026) · Parasite Epidemiology and Control · doi:10.1016/j.parepi.2026.e00554
Self-citation
Metadata
- Authors
- Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., Kassa, M., Assefa, A., & Brhane, B. G.
- Affiliations
- Jimma University (ET)
- Dilla University (ET)
- Corresponding author
- Getu, Eyob
- ORCID
- Venue
- Malaria Journal
- Published
- 2025-06-15
- Volume
- 24
- Issue
- 1
- Pages
- 192-192
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC12168317
- OpenAlex
- W4411317764
- Cited by
- 4
- References
- 37
- Citations by year
- 2026: 3 · 2025: 1
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Malaria Journal (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
- Keywords
- vivax malaria, chloroquine, primaquine, combination antimalarial therapy, treatment efficacy, hemoglobin, antimalarial drug resistance, G6PD testing, treatment safety, Northwest Ethiopia, malaria elimination, malaria elimination strategy
- MeSH terms
- Adolescent, Adult, Antimalarials, Child, Child, Preschool, Chloroquine, Drug Therapy, Combination, Ethiopia, Female, Humans, Male, Middle Aged, Plasmodium vivax, Primaquine, Prospective Studies, Malaria, Vivax, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study. https://app.cochat.ai/papers/10.1186/s12936-025-05446-y
- The paper
- Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., Kassa, M., Assefa, A., & Brhane, B. G. (2025). Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study. Malaria Journal. https://doi.org/10.1186/s12936-025-05446-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.